加载中
NASDAQHealthcareDrug Manufacturers - Specialty & Generic
最新数据
US$17.185
−US$0.305 · -1.74%
Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its business is structured across four primary geographic divisions: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets. The company offers a comprehensive range of pharmaceutical products, encompassing branded prescription medications, generic and complex generic drugs, biosimilar treatments, and active pharmaceutical ingredients (APIs). These offerings target diverse therapeutic areas, addressing both noncommunicable and infectious diseases. Its biosimilars specifically focus on critical conditions in oncology, immunology, endocrinology, ophthalmology, and dermatology. Furthermore, Viatris's APIs are utilized across numerous drug categories, including antibacterials, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitors. Beyond manufacturing medicines, Viatris supports patient well-being through additional services such as diagnostic clinics, educational seminars, and digital tools designed to assist with health management. Products are made available in various forms, including oral solids, injectable solutions, complex dosage formulations, and raw APIs. Viatris distributes these to a broad clientele globally, including retail pharmacies, wholesalers, government bodies, insurance providers, and institutional healthcare facilities. The distribution network involves pharmaceutical wholesalers, retail and institutional pharmacies, mail-order and e-commerce platforms, and specialty pharmacies. The company's extensive portfolio includes prominent brands like Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, Yupelri, Norvasc, Viagra, AMITIZA, Lipacreon, Effexor, Celebrex, and ARV. Its biosimilar franchises feature products such as Fulphila, Ogivri, Hulio, and SEMGLEE. Viatris Inc. also fosters innovation through strategic collaborations and licensing agreements with partners including Revance Therapeutics, Inc., Momenta Pharmaceuticals, Inc., Theravance Biopharma, Inc., Biocon Ltd., and Fujifilm Kyowa Kirin Biologics Co. Ltd. Founded in 1961, Viatris Inc. maintains its corporate headquarters in Canonsburg, Pennsylvania.
常规交易时段
US$17.185
−US$0.305 · -1.74%
盘中时间采用ET。市场数据可能有所延迟。
Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its business is structured across four primary geographic divisions: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets. The company offers a comprehensive range of pharmaceutical products, encompassing branded prescription medications, generic and complex generic drugs, biosimilar treatments, and active pharmaceutical ingredients (APIs). These offerings target diverse therapeutic areas, addressing both noncommunicable and infectious diseases. Its biosimilars specifically focus on critical conditions in oncology, immunology, endocrinology, ophthalmology, and dermatology. Furthermore, Viatris's APIs are utilized across numerous drug categories, including antibacterials, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitors. Beyond manufacturing medicines, Viatris supports patient well-being through additional services such as diagnostic clinics, educational seminars, and digital tools designed to assist with health management. Products are made available in various forms, including oral solids, injectable solutions, complex dosage formulations, and raw APIs. Viatris distributes these to a broad clientele globally, including retail pharmacies, wholesalers, government bodies, insurance providers, and institutional healthcare facilities. The distribution network involves pharmaceutical wholesalers, retail and institutional pharmacies, mail-order and e-commerce platforms, and specialty pharmacies. The company's extensive portfolio includes prominent brands like Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, Yupelri, Norvasc, Viagra, AMITIZA, Lipacreon, Effexor, Celebrex, and ARV. Its biosimilar franchises feature products such as Fulphila, Ogivri, Hulio, and SEMGLEE. Viatris Inc. also fosters innovation through strategic collaborations and licensing agreements with partners including Revance Therapeutics, Inc., Momenta Pharmaceuticals, Inc., Theravance Biopharma, Inc., Biocon Ltd., and Fujifilm Kyowa Kirin Biologics Co. Ltd. Founded in 1961, Viatris Inc. maintains its corporate headquarters in Canonsburg, Pennsylvania.
日内区间
当前US$17.185
52周区间
当前US$17.185
盘中时间采用ET。市场数据可能有所延迟。
Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its business is structured across four primary geographic divisions: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets. The company offers a comprehensive range of pharmaceutical products, encompassing branded prescription medications, generic and complex generic drugs, biosimilar treatments, and active pharmaceutical ingredients (APIs). These offerings target diverse therapeutic areas, addressing both noncommunicable and infectious diseases. Its biosimilars specifically focus on critical conditions in oncology, immunology, endocrinology, ophthalmology, and dermatology. Furthermore, Viatris's APIs are utilized across numerous drug categories, including antibacterials, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitors. Beyond manufacturing medicines, Viatris supports patient well-being through additional services such as diagnostic clinics, educational seminars, and digital tools designed to assist with health management. Products are made available in various forms, including oral solids, injectable solutions, complex dosage formulations, and raw APIs. Viatris distributes these to a broad clientele globally, including retail pharmacies, wholesalers, government bodies, insurance providers, and institutional healthcare facilities. The distribution network involves pharmaceutical wholesalers, retail and institutional pharmacies, mail-order and e-commerce platforms, and specialty pharmacies. The company's extensive portfolio includes prominent brands like Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, Yupelri, Norvasc, Viagra, AMITIZA, Lipacreon, Effexor, Celebrex, and ARV. Its biosimilar franchises feature products such as Fulphila, Ogivri, Hulio, and SEMGLEE. Viatris Inc. also fosters innovation through strategic collaborations and licensing agreements with partners including Revance Therapeutics, Inc., Momenta Pharmaceuticals, Inc., Theravance Biopharma, Inc., Biocon Ltd., and Fujifilm Kyowa Kirin Biologics Co. Ltd. Founded in 1961, Viatris Inc. maintains its corporate headquarters in Canonsburg, Pennsylvania.
日内区间
当前US$17.185
52周区间
当前US$17.185
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 143亿 USD | 147.39亿 USD | 154.27亿 USD | 162.63亿 USD | 178.86亿 USD |
| 销货成本 | 92.86亿 USD | 91.16亿 USD | 89.88亿 USD | 97.66亿 USD | 123.11亿 USD |
| 毛利 | 50.14亿 USD | 56.24亿 USD | 64.39亿 USD | 64.97亿 USD | 55.76亿 USD |
| 研究与开发 | 9.66亿 USD | 8.09亿 USD | 8.05亿 USD | 6.62亿 USD | 6.81亿 USD |
| 销售、一般及管理费用 | 37.94亿 USD | 44.26亿 USD | 46.5亿 USD | 41.79亿 USD | 45.29亿 USD |
| 营业费用 | 76.77亿 USD | 56.14亿 USD | 56.72亿 USD | 48.82亿 USD | 56.1亿 USD |
| 利息支出 | 4.71亿 USD | 5.5亿 USD | 5.73亿 USD | 5.92亿 USD | 6.36亿 USD |
| 折旧和摊销 | 27.98亿 USD | 27.09亿 USD | 27.41亿 USD | 30.28亿 USD | 45.07亿 USD |
| 营业利润 | −26.63亿 USD | 1010万 USD | 7.66亿 USD | 16.15亿 USD | −3400万 USD |
| 净利润 | −35.15亿 USD | −6.34亿 USD | 5470万 USD | 20.79亿 USD | −12.69亿 USD |
公司数据更新于 2026年10月8日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$22.17
上涨空间 29.01%年度分割调整后的每股现金分配。
US$0.48
2025年（完整年度）+100.0% 自从 2006
2026年（部分年度）：US$0.36
US$0.24
2,006
US$0.48
2,022
US$0.48
2,023
US$0.48
2,024
US$0.48
2,025
US$0.36
2,026*
* 在现有股息历史记录中，该日历年仅包含部分期间。
| 行动 | 除息日 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股息 | 2026年8月21日 | US$0.12Quarterly | 2026年8月21日 | 2026年9月16日 |
股息 | 2026年5月22日 | US$0.12Quarterly | 2026年5月22日 | 2026年6月17日 |
股息 | 2026年3月9日 | US$0.12Quarterly | 2026年3月9日 | 2026年3月18日 |
股息 | 2025年11月24日 | US$0.12Quarterly | 2025年11月24日 | 2025年12月15日 |
股息 | 2025年8月22日 | US$0.12Quarterly | 2025年8月22日 | 2025年9月15日 |
股息 | 2025年5月23日 | US$0.12Quarterly | 2025年5月23日 | 2025年6月16日 |
除息 2026年8月21日
US$0.12
Quarterly
2026年8月21日登记 · 支付日 2026年9月16日
除息 2026年5月22日
US$0.12
Quarterly
2026年5月22日登记 · 支付日 2026年6月17日
除息 2026年3月9日
US$0.12
Quarterly
2026年3月9日登记 · 支付日 2026年3月18日
除息 2025年11月24日
US$0.12
Quarterly
2025年11月24日登记 · 支付日 2025年12月15日
除息 2025年8月22日
US$0.12
Quarterly
2025年8月22日登记 · 支付日 2025年9月15日
除息 2025年5月23日
US$0.12
Quarterly
2025年5月23日登记 · 支付日 2025年6月16日
报告持有此股票敞口的交易所交易基金。
State Street SPDR S&P 500 ETF1557.T387.38亿0.03%129.41万亿 JPY0.09%JP¥122,700-0.57%
Vanguard Morningstar Total Stock Market ETFVTI6.12亿0.03%2.3万亿 USD0.03%US$381.03-0.40%
Vanguard S&P 500 ETFVOO5.11亿0.03%1.8万亿 USD0.03%US$714.34-0.26%
Vanguard Morningstar Small-Cap ETFVB4.42亿0.24%1853亿 USD0.03%US$286.98-1.41%
Vanguard Morningstar Small-Cap Value ETFVBR2.81亿0.41%682亿 USD0.05%US$232.17-1.32%
iShares Core S&P 500 ETFIVV2.67亿0.03%8996.25亿 USD0.03%US$780.58-0.25%
State Street SPDR S&P 500 ETFSPY2.45亿0.03%8190.39亿 USD0.09%US$777.22-0.24%
Invesco S&P 500 Equal Weight ETFRSP2.07亿0.21%964.72亿 USD0.20%US$210.6-0.81%State Street SPDR S&P 500 ETF1557.TVanguard Morningstar Total Stock Market ETFVTIVanguard S&P 500 ETFVOOVanguard Morningstar Small-Cap ETFVBVanguard Morningstar Small-Cap Value ETFVBRiShares Core S&P 500 ETFIVVState Street SPDR S&P 500 ETFSPYInvesco S&P 500 Equal Weight ETFRSPAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
